



US 20090148389A1

(19) **United States**

(12) **Patent Application Publication**
Rottiers et al.

(10) **Pub. No.: US 2009/0148389 A1**
(43) **Pub. Date: Jun. 11, 2009**

(54) **INDUCTION OF MUCOSAL TOLERANCE TO ANTIGENS**

(75) Inventors: **Pieter Rottiers**, De Pinte (BE);
Veerle Snoeck, Zingem (BE)

Correspondence Address:
KNOBBE MARTENS OLSON & BEAR LLP
2040 MAIN STREET, FOURTEENTH FLOOR
IRVINE, CA 92614 (US)

(73) Assignee: **ActoGeniX N.V.**, Zwijnaarde (BE)

(21) Appl. No.: **12/094,384**

(22) PCT Filed: **Nov. 29, 2006**

(86) PCT No.: **PCT/EP2006/069062**

§ 371 (c)(1),
(2), (4) Date: **Sep. 12, 2008**

(30) **Foreign Application Priority Data**

Nov. 29, 2005 (EP) 05111467.6

Publication Classification

(51) **Int. Cl.**
A61K 9/12 (2006.01)
A61K 39/395 (2006.01)
A61K 38/20 (2006.01)
A61K 38/21 (2006.01)
A61K 39/02 (2006.01)
A61K 39/00 (2006.01)

(52) **U.S. Cl. 424/45**; 424/158.1; 424/85.2; 424/85.7;
424/234.1; 424/274.1

(57) **ABSTRACT**

Induction of tolerance to antigens by mucosal, preferably oral, delivery of the antigen in combination with an immunomodulating compound producing micro-organism is disclosed. More specifically, Foxp3⁺ and/or IL-10 and/or TGF- β producing regulatory T-cells are induced which are capable of suppressing undesired immune responses toward an antigen. The antigen is preferably delivered orally in combination with an immunosuppressing cytokine secreting micro-organism.